Cover Image
市場調查報告書

吸入型CNS(中樞神經系統)治療藥市場

Inhaled CNS Therapeutics

出版商 Greystone Research Associates 商品編碼 304994
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
吸入型CNS(中樞神經系統)治療藥市場 Inhaled CNS Therapeutics
出版日期: 2014年06月04日 內容資訊: 英文
簡介

神經疾病全球性廣為蔓延。精神及神經疾病造成死亡佔整體1%左右,另一方面疾病負擔佔全球近11%。成65歲以上的人口在絕對量及相對比率中持續增加之下,反轉或改善神經疾病的影響這樣的目標,為了減輕這些疾病帶給社會資金及人的負擔,變得非常重要。數種FDA認證吸入型CNS產品,再加上部分企業推進著神經疾病及CNS(中樞神經系統)疾病為標的之吸入設備藥物輸送系統的開發。

本報告提供吸入型CNS(中樞神經系統)治療藥市場相關分析、市場發展推動因素、處方趨勢、概括競爭環境等的市場動態、吸入技術及平台、設備產品設計因素相關分析彙整、吸入型CNS產品的市場預測、管理方案及指導,以及主要企業簡介等彙整資料,為您概述為以下內容。

摘要整理

CNS治療市場動態

  • 市場發展推動因素
  • 神經疾病與老化
  • 管理護理與醫療費補償
  • 治療藥的處方和處方頻率
  • 競爭環境
  • 風險要素

吸入技術及平台

  • 治療藥的處方
  • 口服吸入設備設計要素
  • 乾燥粉末吸入器
  • 定量吸入器
  • 噴霧器
  • 鼻用吸入劑
  • 鼻腔給藥
  • 鼻腔給藥動力學

設備產品設計因素

  • 生物有效性(生物利用性)
  • 投藥再現性
  • 活性化合物穩定性

吸入型CNS治療藥產品分析、市場資料、預測

  • 下垂體荷爾蒙
  • DDAVP
  • 偏頭痛
    • Migranal
    • Imitrex
    • Zomig
  • 失眠症
    • Zolpimist
  • 疼痛管理
    • Sprix
    • Lazanda/PecFent
  • Butorphanol
  • 思覺失調症
    • Adasuve

開發階段的藥物

  • 帕金森氏症
    • 預約嗎啡
    • CVT301
  • 疼痛管理
    • Fentanyl (AZ-003)
  • 偏頭痛
    • Loxapine (AZ-104)

吸入型CNS市場區隔分析

  • 荷爾蒙療法
  • 偏頭痛
  • 失眠症
  • 疼痛管理
  • 帕金森氏症
  • 精神分裂症

市場要素

  • 管理方案及指導
  • 臨床試驗
  • 治療藥-設備聯盟

企業簡介

目錄
Product Code: CNS555V

The Growing Need for Patient-friendly CNS Therapies

Neurological disorders are highly prevalent worldwide. And while mental and neurological disorders are responsible for about one per cent of deaths, they account for almost 11 per cent of disease burden globally. As the absolute number and relative percentage of people age 65 and older increases, the goal of reversing or ameliorating the effects of neurological disease becomes critical to easing a looming financial and human burden that these diseases will impose on society. Current research is showing potential in increasing the quality of life and delaying cognitive decline for those diagnosed with neurological disease. In addition to the handful of FDA-approved inhaled CNS products, several companies are currently pursuing a range of APIs in inhalation device delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients.

Highlights

  • What are the approved inhaled drugs indicated for neurological diseases and conditions?
  • What are the key CNS market segments within the inhaled drug space?
  • What are the addressable markets and who are the market leaders?
  • What is the breakdown of the market now, and what will it look like in 2020?
  • Who are the market participants, what drugs do they supply, what are their product development activities, business strategies, and corporate alliances and affiliations?
  • How important are pharma-device alliances and design partnerships for successful product development, commercialization and market access?
  • What is the impact of economic, technology, and regulatory factors?

Table of Contents

Executive Summary

CNS Therapeutic Market Dynamics

  • Market Drivers
  • Neurological Diseases and Aging
  • Managed Care and Reimbursement
  • Drug Formulations and Dosing Frequency
  • Competitive Landscape
  • Risk Factors

Inhalation Technology and Platforms

  • Drug Formulations
  • Oral Inhalation Device Design Factors
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Intranasal Inhalation
  • Intranasal Drug Delivery
  • Intranasal Delivery Pharmacokinetics

Device Product Design Factors

  • Bioavailability
  • Dose Reproducibility
  • Active Compound Stability

Inhaled CNS Drug Product Analysis, Market Data and Forecasts

  • Pituitary Hormones
  • DDAVP
  • Migraine
  • Migranal
  • Imitrex
  • Zomig
  • Insomnia
  • Zolpimist
  • Pain Management
  • Sprix
  • Lazanda/PecFent
  • Butorphanol
  • Schizophrenia
  • Adasuve

Development-Stage Drugs

  • Parkinson's Disesae
  • Apomorphine
  • CVT 301
  • Pain Management
  • Fentanyl (AZ-003)
  • Migraine
  • Loxapine (AZ-104)

Inhaled CNS Market Segment Analysis

  • Hormone Therapy
  • Migraine
  • Insomnia
  • Pain Management
  • Parkinson's Disease
  • Schizophrenia

Market Factors

  • Regulatory Initiatives and Guidance
  • Clinical Trials
  • Drug-Device Collaborations

Company Profiles

Back to Top